Synovial Sarcoma Market
                     Synovial Sarcoma
Presented by- DelveInsight Business Research

What is Synovial Sarcoma?
Synovial sarcoma (SS) is a rare sarcoma driven by a translocation 
between SS18 and SSX 1, 2, or 4. The hybrid transcription factor 
SS18:SSX alters SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin 
remodeling and global methylation patterns that may allow future 
therapeutic opportunities.
Current treatment of Synovial Sarcoma involves multimodal approach, incorporating 
surgery, chemotherapy, and radiotherapy. Currently, surgery remains the mainstay for 
treatment of synovial sarcoma. While considering the overall disease management 
perspective, first-line treatment usually consists of wide margin surgery plus 
radiotherapy. However, DelveInsight’s market forecast model is based entirely on 
pharmacological therapies and does not include any procedural or surgical methods.
View Synovial Sarcoma Market Report
As per the latest treatment paradigms, chemotherapy regimen 
is administered for a fixed number of cycles followed by a 
watchful waiting approach to assess the optimum response. 
Doxorubicin and ifosfamide constitute the first-line approach 
generating a large segment of synovial sarcoma’s 
chemotherapeutic market.
How Many Regions Are 
Covered?
● The US
● EU5 (Germany, France, Italy, Spain, 
and the United Kingdom)
● Japan
Doxorubicin with or without ifosfamide remains 
the mainstay of first-line chemotherapy for 
synovial sarcoma treatment although data from 
recent studies suggest that SS patients might 
benefit from first-line combination treatment of 
ifosfamide with doxorubicin over monotherapy 
doxorubicin. However, due to rarity of disease, 
this cannot be considered a final conclusive 
result.
KOL- Views
      To keep up with current market trends, we take KOLs and SME’s opinion 
working in the Synovial Sarcoma domain through primary research to fill the 
data gaps and validate our secondary research. Their opinion helps 
understand and validate current and emerging therapies treatment patterns 
or Synovial Sarcoma market trends. This will support the clients in potential 
upcoming novel treatment by identifying the overall scenario of the market 
and the unmet needs.
What is the Synovial 
Sarcoma Market Report Scope?
● The report covers the descriptive overview of synovial sarcoma, explaining its causes, signs and 
symptoms, physiology, and currently available therapies.
● Comprehensive insight has been provided into the synovial sarcoma epidemiology and treatment 
in the 7MM.
● Additionally, an all-inclusive account of both the current and emerging therapies for synovial 
sarcoma is provided, along with the assessment of new therapies, which will impact the current 
treatment landscape.
● A detailed review of the synovial sarcoma market, historical and forecasted, is included in the 
report, covering drug outreach in the 7MM.
● The report provides an edge while developing business strategies by understanding trends 
shaping and driving the global synovial sarcoma market.
What are the Synovial Sarcoma Market Report 
Highlights?
● In the coming years, the synovial sarcoma market is set to change due to the rising awareness of 
the disease and the favorable environment for new anti-infective modalities, expanding the 
market’s size to enable the drug manufacturers to penetrate more into the market.
● The companies and academics are working to assess challenges and seek opportunities that 
could influence synovial sarcoma R&D. The therapies under development are focused on novel 
approaches to treat/improve the disease condition.
● Major players are involved in developing therapies for synovial sarcoma. The launch of emerging 
therapies will significantly impact the synovial sarcoma market.
● Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, 
and III), different emerging trends, and comparative analysis of pipeline products with detailed 
clinical profiles, key cross-competition, and launch date along with product development 
activities will support the clients in the decision-making process regarding their therapeutic 
portfolio by identifying the overall scenario of the research and development activities.
[email protected]
[email protected]
+91-9650213330
CREDITS: This presentation template was 
created by Slidesgo, including icons by 
DFola tYiconu,  aHnda invfoeg rAapnhiycs  Q& uimeagsetsi obyn  or 
Freepik
Query?
Please keep this slide for attribution
Than
CREDITS: This presentation template was 
created by Slidesgo, including icons by 
Flaticon, and infographics & images by 
kFresepik !